A Phase II Study to Evaluate the Efficacy and Safety of Plasma Replacement with 5[percnt] Albumin in Beta-amyloid Peptide Clearance in Cerebrospinal Fluid and Plasma, and its Clinical Effects in Patients with Mild-Moderate Alzheimer's Disease (P7.107) | Publicación